OncoMatch/Clinical Trials/NCT07019220
Chemoablation for Low-Grade Bladder Cancer
Is NCT07019220 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Gemcitabine for bladder (urothelial, transitional cell) cancer.
Treatment: Gemcitabine — The goal of this single arm, prospective, open-label, investigator-initiated Phase 2 clinical trial is to evaluate the efficacy of intravesical chemoablation in patients with low grade bladder cancer.
Check if I qualifyExtracted eligibility criteria
Disease stage
Grade: low (eau risk)
Prior therapy
Cannot have received: intravesical therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify